[go: up one dir, main page]

AU2001259370A1 - Methods of obtaining active antisense compounds - Google Patents

Methods of obtaining active antisense compounds

Info

Publication number
AU2001259370A1
AU2001259370A1 AU2001259370A AU5937001A AU2001259370A1 AU 2001259370 A1 AU2001259370 A1 AU 2001259370A1 AU 2001259370 A AU2001259370 A AU 2001259370A AU 5937001 A AU5937001 A AU 5937001A AU 2001259370 A1 AU2001259370 A1 AU 2001259370A1
Authority
AU
Australia
Prior art keywords
methods
antisense compounds
obtaining active
active antisense
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259370A
Other languages
English (en)
Inventor
Susan M Freier
Michael C. Giddings
Olga Matveeva
Alexander Tsodikov
Jacqueline R Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
University of Utah Research Foundation Inc
Original Assignee
Isis Pharmaceuticals Inc
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, University of Utah Research Foundation Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2001259370A1 publication Critical patent/AU2001259370A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001259370A 2000-05-09 2001-05-02 Methods of obtaining active antisense compounds Abandoned AU2001259370A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56816500A 2000-05-09 2000-05-09
US09568165 2000-05-09
PCT/US2001/014157 WO2001085996A1 (fr) 2000-05-09 2001-05-02 Procedes pour obtenir des composes anti-sens actifs

Publications (1)

Publication Number Publication Date
AU2001259370A1 true AU2001259370A1 (en) 2001-11-20

Family

ID=24270165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259370A Abandoned AU2001259370A1 (en) 2000-05-09 2001-05-02 Methods of obtaining active antisense compounds

Country Status (4)

Country Link
US (2) US7592440B2 (fr)
EP (1) EP1283908A4 (fr)
AU (1) AU2001259370A1 (fr)
WO (1) WO2001085996A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139917A1 (fr) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Modulation de l'expression de la transthyrétine
CN108135845B (zh) 2015-09-18 2021-10-29 Dnarx公司 用于体内核酸表达的系统和方法
JP2020511521A (ja) 2017-03-23 2020-04-16 ディーエヌエーアールエックス ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5639872A (en) * 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5756710A (en) * 1996-06-05 1998-05-26 The Trustees Of Columbia University In City Of New York Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof
WO1999001139A1 (fr) * 1997-07-03 1999-01-14 Thomas Jefferson University Procede ameliore de conception et de selection d'oligonucleotides antisens efficaces
US5948902A (en) * 1997-11-20 1999-09-07 South Alabama Medical Science Foundation Antisense oligonucleotides to human serine/threonine protein phosphatase genes
US6066625A (en) * 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
AU777499B2 (en) * 1999-04-08 2004-10-21 Gen-Probe Incorporated Antisense oligonucleotides comprising universal and/or degenerate bases

Also Published As

Publication number Publication date
US20040115716A1 (en) 2004-06-17
EP1283908A1 (fr) 2003-02-19
EP1283908A4 (fr) 2003-08-06
US7592440B2 (en) 2009-09-22
US20100113292A1 (en) 2010-05-06
US8202982B2 (en) 2012-06-19
WO2001085996A1 (fr) 2001-11-15

Similar Documents

Publication Publication Date Title
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2001277054A1 (en) Antisense modulation of lysophospholipase i expression
AU2001229493A1 (en) Antisense modulation of mekk2 expression
AU2001229712A1 (en) Reduction of hair growth
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001230515A1 (en) Rigid packet of cigarettes
AU2001277003A1 (en) Antisense inhibition of her-3 expression
AU2001272383A1 (en) Fungicidal combinations of active agents
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU2001245741A1 (en) Antisense inhibition of adam10 expression
AU2002227035A1 (en) Methods of stabilizing fruit-concentrate powders
AU5881001A (en) Method of stabilizing preparation
AU2001258659A1 (en) Improved methods of transfection
AU2001296412A1 (en) Antisense modulation of mekk4 expression
AU2001259370A1 (en) Methods of obtaining active antisense compounds
AU2001290792A1 (en) Antisense modulation of madh6 expression
AU2001288908A1 (en) Antisense modulation of mekk3 expression
GB0030161D0 (en) Improved structure of earphone
AU2002217853A1 (en) Antisense modulation of src-1 expression
AU2002245089A1 (en) Antisense modulation of cytohesin-1 expression
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2001253560A1 (en) Methods of treatment
AU2002216038A1 (en) Preparation of monofluoroalkenes
AU3376501A (en) Improvement of implantation rate